Jazz Pharmaceuticals PLC $JAZZ Stock Holdings Lessened by Granite Investment Partners LLC

Granite Investment Partners LLC lessened its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 50.4% in the third quarter, according to its most recent filing with the SEC. The fund owned 9,175 shares of the specialty pharmaceutical company’s stock after selling 9,309 shares during the period. Granite Investment Partners LLC’s holdings in Jazz Pharmaceuticals were worth $1,209,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of JAZZ. Royal Bank of Canada boosted its position in shares of Jazz Pharmaceuticals by 96.5% in the 1st quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock valued at $8,394,000 after purchasing an additional 33,210 shares during the period. Goldman Sachs Group Inc. lifted its stake in Jazz Pharmaceuticals by 147.7% during the first quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock valued at $43,652,000 after buying an additional 209,667 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Jazz Pharmaceuticals by 4.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock valued at $24,479,000 after buying an additional 7,954 shares in the last quarter. Focus Partners Wealth boosted its holdings in shares of Jazz Pharmaceuticals by 3.4% in the first quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock worth $574,000 after buying an additional 154 shares during the period. Finally, Geneos Wealth Management Inc. increased its position in shares of Jazz Pharmaceuticals by 57.6% in the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 137 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Up 0.6%

Jazz Pharmaceuticals stock opened at $173.25 on Tuesday. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $182.99. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.65 and a quick ratio of 1.44. The firm has a market cap of $10.53 billion, a price-to-earnings ratio of -28.54, a P/E/G ratio of 0.93 and a beta of 0.26. The firm has a fifty day moving average price of $168.00 and a two-hundred day moving average price of $149.83.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on JAZZ shares. Truist Financial upped their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Needham & Company LLC increased their target price on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a report on Monday, January 12th. Robert W. Baird lifted their price target on Jazz Pharmaceuticals from $160.00 to $209.00 and gave the company an “outperform” rating in a report on Tuesday, November 18th. TD Cowen reissued a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Thursday, January 29th. Finally, UBS Group restated a “neutral” rating and set a $188.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Monday, November 24th. Fourteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $205.67.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 4,660 shares of the firm’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $171.20, for a total value of $797,792.00. Following the sale, the chief accounting officer directly owned 7,012 shares in the company, valued at $1,200,454.40. This trade represents a 39.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of the business’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $169.51, for a total transaction of $379,363.38. Following the transaction, the senior vice president owned 19,508 shares in the company, valued at approximately $3,306,801.08. The trade was a 10.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 84,398 shares of company stock valued at $14,957,430 in the last ninety days. Company insiders own 4.30% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.